Essential Elements of Prescription Analgesic Compounding
Essential Elements of Prescription Analgesic Compounding
Essential Elements of Prescription Analgesic Compounding

The Science of Pharmaceutical Compounding: Non-Sterile Training


The Practice-based Activity will provide compounding pharmacists and technicians with the competency to prepare current and viable pharmacotherapeutic non-sterile dosage forms. Unique concepts will be taught facilitating a decision-making process the pharmacist and technician can apply in their day-to-day practice.

Consideration will be given to meeting the physician’s prescription and patient-specific need, compliance-related solutions, medical necessity, and legal and regulatory guidelines. A significant emphasis will be placed on quality assurance and quality control as it relates to dosage form design, pharmaceutical calculations and the validation of preparatory procedures that are part of Master Formulation Records.

Practical techniques and technology-related applications are developed through hands-on experience in a compounding laboratory environment where pharmacists and technicians will be trained in all aspects of non-sterile preparatory procedures. Pharmacists and technicians have the opportunity to develop important aspects of a business development and marketing plan.


Pharmacists and Technicians new to compounding or with an existing compounding practice.


A two part activity; self-study with learning assessment and live event with competency assessment.


  1. Relate unique and essential central core concepts
  2. Describe regulatory framework requirements
  3. Discuss standards of practice for non-hazardous and hazardous drug compounding
  4. Explain components of a standard operating procedure
  5. Apply business, marketing, and sales for a successful practice
  6. Explain characteristics for routes of delivery in non-sterile compounding
  7. Describe the chemical composition of different dosage forms
  8. Identify laboratory practices, procedures and preparatory techniques related to the compounding of non-sterile dosage forms
  9. Relate excipients to dosage forms, chemical composition, and routes of delivery
  10. Relate base types to dosage forms, chemical composition, and routes of delivery
  11. Illustrate the importance of drug monographs and certificates of analysis to compounding
  12. Describe techniques and technology used during compounding
  13. Apply the components of process development
  14. Describe the components of a master formulation record
  15. Discuss the requirements of a compounding record

*For Technicians, please refer to the workbook for Learning Objectives.


  1. Explain compounding as a viable therapeutic option
  2. Express unique marketing messages in support of a compounding practice
  3. Demonstrate the ability to manage expenses and revenues using a financial spreadsheet
  4. Assess acquisition costs in order to establish selling prices related to a compounding practice
  5. Write a standard operating procedure
  6. Apply regulations and standards to a non-hazardous and hazardous drug compounding practice
  7. Develop preparatory procedures for solutions and dispersions; suspensions and emulsions
  8. Solve pharmaceutical calculations used in pharmacy compounding
  9. Relate process development to the establishment of a master formulation record
  10. Prepare a master formulation record
  11. Design a non-sterile compounding facility in compliance with standards of practice
  12. Prepare a series of non-sterile compounded preparations
  13. Apply qualitative and quantitative assessments to compounded preparations

*For Technicians, please refer to the workbook for Learning Objectives.


This CPD event has been accredited for 48 hours of Group-2 CPD (or 96 CPD credits), suitable for inclusion in an individual pharmacists CPD plan.

APC Accredited CPD

A1905MED2: The activity accreditation expires 01 May 2022.



Training and Technical Services Manager, MEDISCA Australia.


CE Program Developer, LP3 Network


Mark Filosi, BSc, RPh

Compounding Pharmacist and Co-Founder, Family Care Pharmacy; Surveyor, ACHC/PCAB


Branko Radojkovic, B Pharm

Pharmacist, Royal Prince Alfred Hospital; Training Facilitator, MEDISCA Australia.

Claire Targett

Pharmacist Capital Chemist Charnwood; Training Facilitator, MEDISCA Australia.

Ken Speidel, RPh, BS Pharm, PharmD, FIACP, FACA

Vice President, Gates Healthcare Associates; Surveyor, ACHC/PCAB; Fellow, IACP and ACA

Kenneth Latta, RPh, BS Pharm, FIACP, FACA

Senior Associate, Gates Healthcare Associates; Senior Associate, Visante; Consultant, North Carolina Board of Pharmacy; Vice

Mark Filosi, BS Pharm, RPh

Compounding Pharmacist and Co-Founder, Family Care Pharmacy; Surveyor, ACHC/PCAB

Patricia Ullmann, B Pharm

Training and Technical Services Manager, MEDISCA Australia.

Rebecca O'Grady, B Pharm, MPS GradCertPharmPrac

Technical Support Services Representative, MEDISCA Australia.

Tammy Nguyen, B Pharm, MPS

Compounding Pharmacist, MEDISCA Australia.

Valentina Karan, B Pharm

Product Development Management, The Compounding Pharmacy Australia; Consultant, MEDISCA Australia.


Activity material is Copyright© 2008-2019 LP3 Network Inc.


Activity participants are required to achieve a 75% passing grade associated with a self-study learning assessment prior to attending the live event. Full attendance and the completion of an activity evaluation and practical skill set competency evaluation are a compulsory requirement to achieve credit for the live event.


This activity is independent of any known bias, prejudice or commercial interest. Both MEDISCA Australia and LP3 Network Inc. assist with the marketing of this activity. LP3 Network Inc. is an independent corporation. LP3 Network Inc. has an established agreement with MEDISCA AUSTRALIA ensuring that it has no influence on LP3 Network Inc. as it relates to activity offerings.


An unrestricted educational grant has been provided by MEDISCA Inc. toward the purchase of electromechanical equipment, reusable and disposable devices, protective and safety supplies, and chemicals specific to compounded medications prepared during laboratory sessions.


Special rates for hotel accommodations have been arranged for activity participants. Payment for hotel accommodations is at the expense of the activity participant.


As a matter of activity programming, meals and refreshments during live activities have been provided by MEDISCA Australia.


A written request must be sent to MEDISCA Australia requesting a ‘Cancellation without Transfer’ to an alternate live activity event date. If cancellation occurs at greater than or equal to 31 days from the live activity event date, then the registrant will receive a 75% refund; 15-30 days is a 50% refund; and less than or equal to 14 days will result in no refund.


The transfer policy is only in effect if requested less than or equal to 15 days post original live activity event date. Failure to submit the “Transfer Request” within 15 days post original live activity event date will default to the “Cancellation and Refund Policy”. The transfer policy can only be applied one (1) time. Transfer to a new live activity event date must be within the current calendar year. Failure to attend the new live activity event will result in no refund and will no longer be transferable. Confirmation of the new activity date is subject to approval by MEDISCA Australia based on the number of available seats within the selected live activity event.



We have placed cookies on your device to help make this website better.

We also use cookies to collect information for making reports and to help us improve the site. The cookies collect information in an anonymous form.

Copyright® 1986-2019 Medisca Inc.
All rights reserved

MEDISCA is ISO 9001:2008 certified